IndyGeneUS AI, Inc. to Acquire the World’s First Blockchain-Mediated Free Market For Genetic Data, EncrypGen

Depiction of silver DNA token
Published on :

IndyGeneUS AI, Inc., to acquire Florida-based EncrypGen, Inc. for an undisclosed amount. The company expects the deal to close in the first quarter of 2022, subject to regulatory approvals and closing conditions.

NeuExcell Therapeutics, Inc. Signs Lease with The Discovery Labs to Establish Corporate Headquarters in the Philadelphia Region

NeuExcell Therapeutics Logo
Published on :

NeuExcell Therapeutics, Inc., a preclinical gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases, today announced the signing of a lease with The Discovery Labs in King of Prussia, PA. This lease sets the stage for NeuExcell to establish their long-term corporate headquarters in the heart of Philadelphia’s Cellicon Valley region and enables the company to build a world-class team tapping into the veteran cell and gene therapy talent in Greater Philadelphia.

Red Cell Forms Zephyr AI to Revolutionize Drug Discovery and Precision Medicine

Zephyr AI Logo
Published on :

Zephyr AI’s mission is to transform drug discovery, redefine personalized medicine, and empower healthcare systems to achieve better patient outcomes at lower cost. Zephyr AI integrates artificial intelligence with extensive datasets to upend traditional “guess and test” drug development and personalized medicine processes to unearth novel therapeutics, new applications for existing therapeutics, and advanced biomarkers for individualized treatments.

PhaseBio Names Jonathan Birchall as Chief Commercial Officer

PhaseBio Logo
Published on :

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer.